Immune-based identification of cancer patients at high risk of progression

Yann-Alexandre Vano; Florent Petitprez; Nicolas A Giraldo; Wolf H Fridman; Catherine Sautès-Fridman

doi:10.1016/j.coi.2018.03.005

Immune-based identification of cancer patients at high risk of progression

Curr Opin Immunol. 2018 Apr:51:97-102. doi: 10.1016/j.coi.2018.03.005. Epub 2018 Mar 16.

Authors

Yann-Alexandre Vano¹, Florent Petitprez², Nicolas A Giraldo³, Wolf H Fridman⁴, Catherine Sautès-Fridman⁵

Affiliations

¹ INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, F-75006 Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; University UPMC Paris 6, Sorbonne University, UMR_S1138-75006 Paris, France; Department of Medical Oncology, Georges Pompidou European Hospital, University Descartes Paris 5, Paris, France.
² INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, F-75006 Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; University UPMC Paris 6, Sorbonne University, UMR_S1138-75006 Paris, France; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.
³ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.
⁴ INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, F-75006 Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; University UPMC Paris 6, Sorbonne University, UMR_S1138-75006 Paris, France.
⁵ INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, F-75006 Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; University UPMC Paris 6, Sorbonne University, UMR_S1138-75006 Paris, France. Electronic address: [email protected].

PMID: 29554496
DOI: 10.1016/j.coi.2018.03.005

Abstract

Tumors are highly heterogeneous structures where malignant cells interact with a large variety of cell populations, including a clinically-relevant immune component. We review and compare the most recent methods designed to analyze and quantify the composition of immune and stromal microenvironment of tumors and discuss their use in identification of patients for high risk of progression. If the impact of the various immune components on patient's relapse share common rules in most malignancies, clear cell renal cell tumors behave differently with regards to immunity. We focus on this specific pathology to show how the tumor interacts with the host's immune system and how this intricate relationship shapes the clinical outcome.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Disease Progression
Disease Susceptibility / immunology
Humans
Immune System
Lymphocytes, Tumor-Infiltrating / immunology
Lymphocytes, Tumor-Infiltrating / metabolism
Lymphocytes, Tumor-Infiltrating / pathology
Neoplasms / diagnosis*
Neoplasms / immunology*
Neoplasms / metabolism
Neoplasms / mortality
Recurrence
Risk Assessment
Tumor Microenvironment / immunology*